Table 2.
Comparisons of clinical characteristics between the development cohort and the validation cohort.
| Development cohort | Validation cohort | p | |
|---|---|---|---|
| Characteristic | n = 285 | n = 95 | |
| Sex | 0.05 | ||
| Male | 255 (89.5) | 77 (81.1) | |
| Female | 30 (10.5) | 18 (18.9) | |
| Age (years) | 0.668 | ||
| Median | 47.00 | 47.00 | |
| Range | 23–71 | 24–72 | |
| IQR | 38.00–54.00 | 40.50–54.00 | |
| HBsAg | 0.373 | ||
| Negative | 39 (13.7) | 9 (9.5) | |
| Positive | 246 (86.3) | 86 (90.5) | |
| HBV-DNA (copies/ml) | 0.184 | ||
| <500 | 98 (34.4) | 25 (26.3) | |
| ≥500 | 187 (65.6) | 70 (73.7) | |
| AFP level (ng/ml) | 0.211 | ||
| <400 | 121 (42.5) | 48 (50.5) | |
| ≥400 | 164 (57.5) | 47 (49.5) | |
| Tumor size (cm)† | 0.702 | ||
| Median | 8 | 8 | |
| Range | 2–20 | 3–20 | |
| IQR | 6.00–11.00 | 6.00–11.00 | |
| Edmondson grade† | 0.585 | ||
| Poorly differentiated | 109 (38.2) | 40 (42.1) | |
| Moderately and well-differentiated | 176 (61.8) | 55 (57.9) | |
| Node number | 0.232 | ||
| <3 | 212 (74.4) | 64 (67.4) | |
| ≥3 | 73 (25.6) | 31 (32.6) | |
| Tumor capsule | 0.581 | ||
| Complete | 182 (63.9) | 57 (64.9) | |
| Incomplete | 103 (36.1) | 38 (40.0) | |
| Resection margin (cm) | 0.946 | ||
| <1 | 213 (74.7) | 70 (73.7) | |
| ≥1 | 72 (25.3) | 25 (26.3) | |
| Ki67 | 0.365 | ||
| Median | 0.40 | 0.40 | |
| Range | 0.03–0.95 | 0.05–0.90 | |
| IQR | 0.20–0.60 | 0.15–0.60 | |
| MVI | 0.274 | ||
| No | 55 (19.3) | 24 (25.3) | |
| Yes | 230 (80.7) | 71 (74.7) | |
| PVTT | 1.00 | ||
| No | 215 (75.4) | 72 (75.8) | |
| Yes | 70 (24.6) | 23 (24.2) | |
| Liver cirrhosis | 1.00 | ||
| None/mild | 211 (74.0) | 71 (74.7) | |
| Moderate/severe | 74 (26.0) | 24 (25.3) | |
| Postoperative complications | 0.38 | ||
| No | 253 (88.8) | 94 (92.6) | |
| Yes | 32 (11.2) | 7 (7.4) |
†
In cases involving multiple nodes, only the largest was indicated. Data are presented as n (%) by group and compared using the Pearson chi-square test or Fisher’s exact test for any cell number < 5. CNLC: China liver cancer; HBV: Hepatitis B virus; HR: Hepatic resection; MVI: Microvascular invasion; PA-TACE: Postoperative adjuvant transarterial chemoembolization; PVTT: Portal vein tumor thrombus.